Viracta Historical Balance Sheet
VIRX Stock | USD 0.17 0.01 6.25% |
Trend analysis of Viracta Therapeutics balance sheet accounts such as Total Assets of 54.4 M, Short Long Term Debt Total of 14.3 M, Other Current Liabilities of 5.5 M or Total Current Liabilities of 40.3 M provides information on Viracta Therapeutics' total assets, liabilities, and equity, which is the actual value of Viracta Therapeutics to its prevalent stockholders. By breaking down trends over time using Viracta Therapeutics balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.
Financial Statement Analysis is much more than just reviewing and examining Viracta Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Viracta Therapeutics is a good buy for the upcoming year.
Viracta |
About Viracta Balance Sheet Analysis
Balance Sheet is a snapshot of the financial position of Viracta Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Viracta Therapeutics Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Viracta Therapeutics and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Viracta currently owns. An asset can also be divided into two categories, current and non-current.
Viracta Therapeutics Balance Sheet Chart
Add Fundamental
Total Assets
Total assets refers to the total amount of Viracta Therapeutics assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Viracta Therapeutics books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.Total Current Liabilities
Total Current Liabilities is an item on Viracta Therapeutics balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Viracta Therapeutics are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.Total Stockholder Equity
The total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders.Liabilities And Stockholders Equity
The total of all liabilities and equity in the company, which should equal the company's total assets according to the accounting equation.Capital Lease Obligations
Viracta Therapeutics capital lease obligations are the amount due for long-term lease agreements that are nearly equivalent to Viracta Therapeutics asset purchases. For example, Viracta Therapeutics can use a capital lease to finance the purchase of an asset without ever buying it. A capital lease gives companies such as Viracta Therapeutics control over an asset for a big portion of its life. The total obligations of a company under capital leases, which are lease agreements that transfer substantially all risks and rewards of ownership to the lessee.Most accounts from Viracta Therapeutics' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Viracta Therapeutics current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Viracta Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For more information on how to buy Viracta Stock please use our How to Invest in Viracta Therapeutics guide.At this time, Viracta Therapeutics' Property Plant And Equipment Gross is fairly stable compared to the past year. Accumulated Other Comprehensive Income is likely to rise to 9,450 in 2024, whereas Total Assets are likely to drop slightly above 54.4 M in 2024.
2021 | 2022 | 2023 | 2024 (projected) | Short and Long Term Debt Total | 5.5M | 25.2M | 25.6M | 14.3M | Total Assets | 108.6M | 96.0M | 56.7M | 54.4M |
Viracta Therapeutics balance sheet Correlations
Click cells to compare fundamentals
Viracta Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Viracta Therapeutics balance sheet Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 37.2M | 48.3M | 108.6M | 96.0M | 56.7M | 54.4M | |
Short Long Term Debt Total | 6.3M | 6.2M | 5.5M | 25.2M | 25.6M | 14.3M | |
Other Current Liab | 2.5M | 3.4M | 5.4M | 6.9M | 10.1M | 5.5M | |
Total Current Liabilities | 9.4M | 6.3M | 9.1M | 10.0M | 38.4M | 40.3M | |
Total Stockholder Equity | 27.5M | (46.2M) | 94.4M | 61.1M | 18.3M | 19.5M | |
Property Plant And Equipment Net | 820K | 1.0M | 882K | 414K | 464K | 749.7K | |
Net Debt | (12.0M) | (40.9M) | (98.1M) | (11.6M) | 13.2M | 13.9M | |
Retained Earnings | (682.8M) | (50.9M) | (165.7M) | (214.9M) | (265.9M) | (279.2M) | |
Accounts Payable | 791K | 1.6M | 2.9M | 2.5M | 2.4M | 1.7M | |
Cash | 18.3M | 47.1M | 103.6M | 36.8M | 12.3M | 24.1M | |
Non Current Assets Total | 918.0K | 1.1M | 3.3M | 2.2M | 1.7M | 1.1M | |
Non Currrent Assets Other | 98.0K | 76K | 2.4M | 1.8M | 1.3M | 1.3M | |
Cash And Short Term Investments | 34.6M | 47.1M | 103.6M | 91.0M | 53.7M | 51.5M | |
Common Stock Shares Outstanding | 2.5M | 92.8K | 31.9M | 37.8M | 38.6M | 40.6M | |
Liabilities And Stockholders Equity | 37.2M | 48.3M | 108.6M | 96.0M | 56.7M | 54.4M | |
Non Current Liabilities Total | 8K | 281.0K | 88.2M | 5.1M | 24.9M | 0.0 | |
Other Current Assets | 1.7M | 220K | 3.4M | 4.5M | 1.1M | 1.6M | |
Other Stockholder Equity | 698.6M | 4.7M | 254.6M | 270.7M | 278.8M | 292.7M | |
Total Liab | 9.7M | 94.5M | 14.2M | 34.9M | 38.4M | 27.6M | |
Property Plant And Equipment Gross | 820K | 273K | 882K | 414K | 464K | 717.8K | |
Total Current Assets | 36.3M | 47.2M | 105.3M | 93.7M | 55.0M | 52.9M | |
Accumulated Other Comprehensive Income | 1K | (5.5M) | 0.0 | (178K) | 9K | 9.5K | |
Short Term Debt | 6.0M | 1.4M | 762K | 556K | 25.8M | 27.1M | |
Common Stock | 3K | 4K | 11K | 1K | 4.6K | 4.9K | |
Capital Surpluse | 698.6M | 718.8M | 254.6M | 270.7M | 243.6M | 436.4M | |
Property Plant Equipment | 117.1K | 1.0M | 242K | 148K | 170.2K | 245.8K | |
Other Assets | 1.0 | 76.4K | 0.0 | 1.8M | 2.1M | 2.2M | |
Net Tangible Assets | (28.4M) | (46.2M) | 89.2M | 55.7M | 64.0M | 67.2M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Viracta Stock Analysis
When running Viracta Therapeutics' price analysis, check to measure Viracta Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Viracta Therapeutics is operating at the current time. Most of Viracta Therapeutics' value examination focuses on studying past and present price action to predict the probability of Viracta Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Viracta Therapeutics' price. Additionally, you may evaluate how the addition of Viracta Therapeutics to your portfolios can decrease your overall portfolio volatility.